CAS 1225497-78-8

ON-01910

Description:

ON-01910, with the CAS number 1225497-78-8, is a small molecule that has garnered attention in the field of cancer research due to its potential as an anti-cancer agent. It functions primarily as a selective inhibitor of the protein kinase, which plays a crucial role in various cellular processes, including cell growth and division. The compound has been studied for its ability to induce apoptosis (programmed cell death) in cancer cells and to inhibit tumor growth in preclinical models. ON-01910 is characterized by its unique chemical structure, which allows it to interact specifically with target proteins involved in cancer progression. Additionally, it has shown promise in overcoming resistance to other cancer therapies, making it a candidate for combination treatments. Its pharmacological profile includes properties such as solubility and stability, which are essential for its efficacy and bioavailability in therapeutic applications. Ongoing research continues to explore its mechanisms of action and potential clinical applications in oncology.

Formula: C₂₁H₂₄NNaO₈S

Synonyms:

• ON-01910
• ON 01910 sodium salt
• ON-01910;ESTYBON
• ON-01910 USP/EP/BP
• ON-01910; ON01910; ON 01910
• brand name: Estybon.
• Rigosertib (ON-01910)
• 2-[2-methoxy-5-[2-(2,4,6-trimethoxyphenyl)vinylsulfonylmethyl]anilino]acetic acid
• ON-01910 (rigosertib)
• N-[2-Methoxy-5-[[[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]glycine sodium salt Rigosertib (ON-01910)
• ON01910; ON 01910; ON-01910; RIGOSERTIB SODIUM; BRAND NAME: ESTYBON.
• N-[2-methoxy-5-[[[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-glycine,sodium salt (1:1)
• Estybon
• Rigosertio
• on 1910 sodium salt
• CS-551
• Rigosertib Sodium(Random Configuration)
• N-[2-Methoxy-5-[[[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]glycine sodium salt
• Rigosertib sodium salt
• sodium 2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetate|||
• Sodium (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetate

Glycine, N-[2-methoxy-5-[[[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, sodium salt (1:1)

CAS: 1225497-78-8

Formula: C₂₁H₂₄NNaO₈S

Purity: 99%

Color and Shape: Solid

Molecular weight: 473.4719

Ref: IN-DA0017G2

(E/Z)-Rigosertib sodium

CAS: 1225497-78-8

(E/Z)-Rigosertib sodium

Purity: ≥95%

Molecular weight: 473.47g/mol

Ref: 54-BUP13084

(E/Z)-Rigosertib sodium

CAS: 1225497-78-8

ON-01910 is a non-ATP-competitive PLK1 inhibitor(IC50 of 9 nM, in a cell-free assay).

Formula: C₂₁H₂₄NNaO₈S

Purity: 98.56% - 99.82%

Color and Shape: Solid

Molecular weight: 473.47

Ref: TM-T6070

ON-01910 Sodium Salt

Controlled Product

CAS: 1225497-78-8

Applications Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of Polo-like kinase 1 (PLK1).
References Gumireddy, K., et al.: Cancer Cell, 7, 275 (2005); Reddy, M., et al.: J. Med. Chem., 54, 6254 (2011)

Formula: C₂₁H₂₄NNaO₈S

Color and Shape: Neat

Molecular weight: 473.47

Ref: TR-O657000

Rigosertib

CAS: 1225497-78-8

Rigosertib is a small molecule that inhibits the activity of the protein ErbB2. It has been shown to induce reactive oxygen species (ROS) and inhibit tumor growth in preclinical models. Rigosertib is being investigated as an investigational agent for cancer therapeutics. It has been shown to be well tolerated in animals and humans with minimal toxicity. Rigosertib prevents cell-cell interactions by binding to EGFR, which may have therapeutic potential in squamous cell carcinomas and melanoma cells. Rigosertib also inhibits the activity of tyrosine kinases and may be useful for treatment of cancers that are resistant to other therapies, such as coumarin derivatives, which are used in combination with chemotherapy for treatment of acute myeloid leukemia. RIGSERTIB blocks tumor growth by inducing apoptosis through activation of caspase-3 and caspase-7 pathways, which causes DNA fragmentation, nuclear condensation, and cleavage of poly

Purity: Min. 95%

Ref: 3D-FR137713